SCHEMBL22080175

SCHEMBL22080175

COP(=O)(S)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(S)OC[C@@H]1C[C@@H](F)[C@H](n2cnc3c(=O)[nH]c(N)nc32)O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NT5E P21589 1/20 0.49
▸ FUT5 Q11128 1/20 0.49
▸ STING1 Q86WV6 9/20 0.47
▸ DNPH1 O43598 1/20 0.47
▸ PRKAB2 O43741 1/20 0.47
▸ TRPM2 O94759 1/20 0.47
▸ LDHA P00338 1/20 0.47
▸ ADRB2 P07550 1/20 0.47
▸ FBP1 P09467 1/20 0.47
▸ SRC P12931 1/20 0.47
▸ ADORA1 P30542 1/20 0.47
▸ P2RY2 P41231 1/20 0.47
▸ P2RY1 P47900 1/20 0.47
▸ PRKAG1 P54619 1/20 0.47
▸ PRKAA2 P54646 1/20 0.47
▸ PDE4D Q08499 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ PRKAA1 Q13131 1/20 0.47
▸ PDE3A Q14432 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23476877 0.94 NT5E (0.52) NT5EFUT5STING1DNPH1PRKAB2
SCHEMBL22080177 0.93 NT5E (0.46) NT5EFUT5STING1DNPH1PRKAB2
SCHEMBL23542559 0.90 STING1 (0.47) NT5EFUT5STING1
SCHEMBL27112566 0.90 STING1 (0.45) NT5ESTING1
SCHEMBL27121433 0.90 STING1 (0.45) NT5ESTING1
SCHEMBL22080509 0.89 NT5E (0.48) NT5EFUT5STING1P2RY2TAS1R3
SCHEMBL20326926 0.88 STING1 (0.48) NT5ESTING1
SCHEMBL20324531 0.87 STING1 (0.49) NT5EFUT5STING1
SCHEMBL20324741 0.87 STING1 (0.49) NT5EFUT5STING1
SCHEMBL22083402 0.87 STING1 (0.49) NT5EFUT5STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040053-B2 Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling CHINOOK THERAPEUTICS, INC. (US) 2021-06-22 — — US disclosed
US-20200179431-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING Aduro Biotech, Inc. (US) 2020-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200179431-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING STING1, IRF3, CGAS NT5E 115/4885FUT5 2144/4885STING1 1/4885
US-11040053-B2 Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling STING1, IRF3, CGAS NT5E 144/4885FUT5 2255/4885STING1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback